CAP TODAY Pathology/Laboratory Medicine/Laboratory Management
At the AACC Show 2014
September 2014—Immucor’s PreciseType HEA test is an FDA-approved molecular assay designed to provide clinicians and blood banks with the detailed genetic matching information they need to reduce the risk of alloimmunization and serious hemolytic reactions, which is especially problematic for patients receiving frequent blood transfusions.
Unlike traditional serology-based testing, the DNA-based PreciseType test can identify 35 red blood cell antigens from 11 blood groups simultaneously. This enables the complete blood typing of patients and donors for increased transfusion compatibility. The PreciseType test also simplifies the process of identifying donors with rare or unusual antigens so blood banks can distinguish and save scarce units for special cases. The test has been CE marked in Europe for IVD use since 2010.
Immucor, 770-441-2051